linjc16/ctgov huggingface dataset:
Study of Sildenafil in Patient With Heart Failure.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if sildenafil (Viagra) improves exercise tolerance.

Detailed Description
-----------------
Patients will undergo an exercise stress test. One dose of Sildenafil will then be given, followed by a one hour rest period. A repeat exercise stress test will then be repeated.

Official Title
-----------------
Measurement of the Effect of Sildenafil Citrate (Viagra) on the Hemodynamics of Exercise Tolerance in Advanced Congestive Heart Failure.

Conditions
-----------------
Congestive Heart Failure

Intervention / Treatment
-----------------
* Drug: sildenafil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 - 75 Ejection fraction <35% Heart failure limited by fatigue and shortness of breath - Exclusion Criteria: Inability to exercise. Patients with shortness of breath while resting. Patient requiring intravenous medication. Patients taking the following medications: nitroglycerine pill/patch/paste, isordil and Imdur -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: sildenafil|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients will have exercise capacity measured by an exercise stress test before and after one dose of sildenafil. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Exercise stress test
Synchronizing Blastocyst in Frozen Embryo Transfer

Study Overview
=================
Brief Summary
-----------------
The aim of the present study is to determine if implantation rate could be increased in women undergoing frozen embryo transfer cycles in case of adjusting their embryo development at hatching stage.

Official Title
-----------------
Synchronizing Blastocyst at Hatching Stage in Frozen Embryo Transfer Cycles

Conditions
-----------------
Embryo Implantation

Intervention / Treatment
-----------------
* Other: synchronizing blastocysts


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who will agree to participate and assign an informed consent form Only blastocyst transfer FET cycles Patients undergoing FET after their 1st IVF or ICSI cycle with no pregnancy at the fresh transfer Freeze-all cycles due to OHSS Freeze-all cycles due to poor endometrium Age 19-33 at the time of randomization. Their frozen blastocysts are 3 or less grade of expansion. Female with a ≥12 AFCs Endometrial thickness ≥ 8mm at the time of ovulation Women with their male partners will give only fresh semen Women who have no uterine abnormality by ultrasound BMI ≤ 31 Exclusion Criteria: Cycles undergoing preimplantation genetic diagnosis. Women who have previous two cycles of implantation failure at fresh transfer Women who have previous two FET failed cycles Any uterine pathology (myomas, adenomyosis, endocrinopathies, thrombophilia, chronic pathologies, acquired or congenital uterine abnormalities) Patients with severe endometriosis Presence of uni- or bilateral hydrosalpinx Recurrent pregnancy loss. Any medical condition that affect fertility.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 33 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: frozen/thawed<br>blastocysts with three or less grade of expansion will be thawed and then subsequently transferred into women uterus three hours post-thawing. | |
| Experimental: synchronized frozen/thawed hatching blastocysts<br>blastocyst thawing (with three or less grade of expansion) will take place the day before embryo transfer in order to reach hatching stage | Other: synchronizing blastocysts<br>* transferring frozen/thawed a synchronized blastocysts at hatching stage into female uterus.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ongoing implantation rate | ultrasound detection of ongoing gestational sacs with heartbeats after 12 weeks of gestation per transferred embryos | 12 weeks |
Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to compare the effects of recombinant factor VIIa (NovoSeven) on restoring coagulation activation between patients with hemophilia A and antibodies to factor VIII and normal subjects (controls) by use of an in vivo method.

Official Title
-----------------
Effects of Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation in Patients With Hemophilia A and Antibodies to Factor VIII

Conditions
-----------------
Hemophilia A

Intervention / Treatment
-----------------
* Drug: NovoSeven


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients with hemophilia A and current antibodies to factor VIII - Exclusion Criteria: Life-threatening hemorrhage Severe liver failure Any other severe co-morbidity (including diabetes mellitus, renal failure, cancer, septicemia, disseminated intravascular coagulation, crush injury) Exposure to other haemostatic drugs during the previous 7 days Hypersensitivity to hamster, mouse or bovine proteins Known or suspected allergy to NovoSeven or any of its components

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: NovoSeven|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
factor VIII inhibitor
Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resistant to platinum-based chemotherapy.

Conditions
-----------------
Ovarian Neoplasms

Intervention / Treatment
-----------------
* Drug: TLK286


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Histologic diagnosis of ovarian cancer Recurrent or persistent disease following primary therapy Measurable disease Prior treatment with at least one but no more than three prior chemotherapy regimens Resistant or refractory to platinum-based chemotherapy At least 18 years of age Good performance status (ECOG 0 to 1) Adequate liver, renal and bone marrow function Exclusion criteria Pregnant or currently breast feeding Treatment with chemotherapy or immunotherapy within four weeks Prior radiation to the whole pelvis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: TLK286|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Open-Label Placebo for Functional Dyspepsia

Study Overview
=================
Brief Summary
-----------------
The study is evaluating the efficacy of open-label placebo for the treatment of functional dyspepsia.

Official Title
-----------------
Open-Label Placebo for Functional Dyspepsia

Conditions
-----------------
Dyspepsia

Intervention / Treatment
-----------------
* Drug: Placebos


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Functional Dyspepsia Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Arm 1: open-label placebo Arm 2: treatment as usual control
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: open-label placebo<br>open-label placebo | Drug: Placebos<br>* placebo pills<br>|
| No Intervention: treatment as usual<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| dyspepsia severity on a VAS from 0-100 | How severe have your dyspepsia symptoms been over the past 7 days (on a VAS from 0-100)? | 3 weeks |
REBOA for Out-of-hospital Cardiac Arrest

Study Overview
=================
Brief Summary
-----------------
Cardiac arrest is a major health problem that carries a high mortality rate. Substantial research and development have been put into changing the outcome of cardiac arrest and despite the advent of automated external defibrillators (AED), increase in bystander Cardiopulmonary resuscitation (CPR) and automated CPR devices (ACPR), the proportion of patient survival to hospital discharge has only minimally improved. The objective is to investigate safety and performance of the Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) procedure as an adjunct to Advanced Life Support (ALS) for treatment of refractory cardiac arrest.

Detailed Description
-----------------
The scope of the study is to collect data on patients with refractory out of hospital cardiac arrest (OHCA) for this feasibility study. Data collected: from enrolment of the patient until hospital arrival every 24 hours at discharge or 7 days post enrollment at 30 days post enrollment The investigation is initiated to investigate the safety and performance of the REBOA procedure for patients experiencing refractory OHCA.

Official Title
-----------------
REBOA for Out-of-hospital Cardiac Arrest

Conditions
-----------------
Cardiac Arrest

Intervention / Treatment
-----------------
* Procedure: REBOA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Witnessed cardiac arrest Bystander or professional CPR within 5 minutes Refractory cardiac arrest Exclusion Criteria: End Tidal CO2 <1,3 kPa Traumatic cardiac arrest Women with known pregnancy Patients with known terminal disease Patients with known do-not-attempt-CPR order Patients with overdose

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: REBOA<br> | Procedure: REBOA<br>* Endovascular balloon occlusion of the aorta<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Central blood pressure |  | 1 hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Return of spontaneous circulation (ROSC) |  | 1 hour | 
| Changes in cardiac rhythm following balloon inflation |  | 1 hour | 
| During procedure - time from first needle stick to successful sheath insertion |  | 1 hour | 
| During procedure - time from first needle stick to finalized balloon inflation |  | 1 hour | 
| End-tidal CO2 (EtCO2) |  | 1 hour |
Study of Peri-Operative Docetaxel Plus Laparoscopic Radical Prostatectomy in Prostate Cancer Patients

Study Overview
=================
Brief Summary
-----------------
This is a prospective phase II study of peri-operative docetaxel plus laparoscopic radical prostatectomy in patients with localized Gleason 7 pT2a-pT2b adenocarcinoma of the prostate and a risk of relapse after radical prostatectomy.

Official Title
-----------------
A Prospective Phase II of Peri-Operative Docetaxel + Laparoscopic Radical Prostatectomy in Patients With Localized Gleason 7 pT2a-pT2b Adenocarcinoma and a Risk of Relapse After Radical Prostatectomy

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Drug: docetaxel
* Procedure: laparoscopic radical prostatectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 18 years and less than 70 years Histologically-proven Gleason 7 adenocarcinoma of the prostate pT2a or pT2b disease based on biopsies of the prostate More than 2/3 of positive biopsies or 15 ≤ serum PSA <20 No previous carcinoma, except basal-cell carcinoma of the skin Adequate renal function: measured or calculated creatinine clearance> 60 ml/min Absolute granulocyte count ≥ 1,500/mm3, platelets ≥ 100,000 mm3, bilirubin ≤ 1.5 fold the upper normal value Signed informed consent. Exclusion Criteria: Patients infected by the Human Immunodeficiency Virus (HIV) Contra-indication to general anesthesia or surgery Patients who do not fit inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: docetaxel|nan|
|Procedure: laparoscopic radical prostatectomy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complete prostate specific antigen (PSA) response rate |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Toxicity |  |  | 
| Pathological response rate |  |  | 
| Progression free survival |  |  | 
| Overall survival |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Patients with localized Gleason 7 pT2a-pT2b adenocarcinoma of the prostate
Efficacy of Topical Ketorolac Versus Placebo for Improving Visual Outcomes Following Multifocal IOL Implantation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to evaluate the efficacy of ketorolac 0.4% on quality of vision and macula thickening in patients undergoing cataract surgery using the ReStor® multifocal IOL.

Conditions
-----------------
Macula Thickening

Intervention / Treatment
-----------------
* Drug: Prednisolone Acetate
* Drug: Ketorolac 0.4%
* Drug: Gatifloxacin 0.3%


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males or females > 50 years old Scheduled to undergo bilateral phacoemulsification with implantation of a multifocal IOL. Likely to complete all study visits and able to provide informed consent Visual potential of 20/25 or better Exclusion Criteria: · Prior use of topical ketorolac Known contraindications to any study medication or ingredients Active ocular diseases or uncontrolled systemic disease Active ocular allergies

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Prednisolone Acetate|nan|
|Drug: Ketorolac 0.4%|nan|
|Drug: Gatifloxacin 0.3%|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Inter-observer Reproductibility of Visual Estimation of Left Ventricular Ejection Fraction in Critical Care

Study Overview
=================
Brief Summary
-----------------
Inter-observer reproductibility of visual estimation of left ventricular ejection fraction is known to be good in cardiology but has not been studied in ICU. The goal of the study is to determine if this reproductibility is good enough.

Official Title
-----------------
Inter-observer Reproductibility of Visual Estimation of Left Ventricular Ejection Fraction in Critical Care

Conditions
-----------------
Ventricular Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: practitioners working in intensive care. age > 18 years Exclusion criteria: - Age under 18

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| reproductibility of LVEF in percentage | reproductibility of LVEF in percentage | day 1 |
Immune Response and Cytomegalovirus in Intensive Care Unit (ICU) Patients

Study Overview
=================
Brief Summary
-----------------
This prospective study evaluate the immune status of patients admitted in ICU.CMV remains dormant in the body, but in people with immune deficiency, CMV could reactivate and cause life-threatening pneumonia.

Detailed Description
-----------------
Candidates will be screened with medical history and blood tests.Then, 2 groups of 20 patients (with or without CMV reactivation) matched for CMV status will be compared for their immune system against CMV.

Official Title
-----------------
Cellular Immunity, Cytomegalovirus Infection and Septic Shock in ICU Patients

Conditions
-----------------
Cytomegalovirus Infection

Intervention / Treatment
-----------------
* Other: Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings
* Other: Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age more than 18-year-old Informed consent Exclusion Criteria: minors, pregnant or lactating women, adults under guardianship, immunosuppression at the entrance to resuscitation, AIDS

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Infection to CMV | Other: Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings<br>* Sampling of blood<br>|
| Other: 2<br>Group control CMV | Other: Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings<br>* Sampling of blood<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bring to light the quantitative and qualitative immunological modifications of the present cells NK before the arisen of an infection to CMV |  | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bring to light the quantitative and qualitative immunological modifications of cells NK in the consequences of an infectious shock |  | 24 months |
Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab

Study Overview
=================
Brief Summary
-----------------
This study will quantify the intraocular pressure elevation in the immediate time period following intravitreous injection. With more widespread use of intravitreous injections in patients that may require several injections per year, it is important to document the sudden increase in intraocular pressure, including the maximum intraocular pressure and the time required for the intraocular pressure to return to baseline. This data may be useful in stimulating additional studies to evaluate the long term ocular effects of repeated intravitreous injections. We hypothesize that the intraocular pressure increases significantly following intravitreous injection and then returns to baseline during the initial thirty minutes following ranibizumab injection.

Detailed Description
-----------------
We will assess the trend of intraocular pressure immediately following intravitreal injection of ranibizumab 0.5 mg (0.05 mL) by taking serial intraocular pressure readings every five minutes for thirty minutes after injection. This study is a prospective descriptive data collection consisting of measuring intraocular pressure immediately following intraocular injection, and at 5, 10, 15, 20, 25, and 30 minutes following injection of ranibizumab 0.5 mg.

Official Title
-----------------
A Prospective Investigation of the Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab

Conditions
-----------------
Choroidal Neovascularization

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or Female Patients >18 years of age Patients will have documented choroidal neovascular membranes on fluorescein angiogram and/or optical coherence tomography Requiring treatment or maintenance therapy for choroidal neovascular membrane Able and willing to provide written informed consent Exclusion Criteria: History of arterial occlusive disease of the eye. History of advanced glaucoma.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intraocular Pressure, Intravitreous Injection, Ranibizumab